Search Results 171-180 of 6021 for albumin

1. A Study to Compare the Effectiveness, Safety and Tolerability of P1101 vs. Anagrelide for Essential Thrombocythemia - Mayo Clinic

   ... albumin >3.5 g/dL, alanine aminotransferase ≤2.0 x ULN, aspartate aminotransferase ≤2.0 x ULN at screening 11. Creatinine clearance ≥40 mL/min (by ...

2. Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

   - Serum albumin ≥ 3.5 g/dL; - Serum Alkaline Phosphatase (ALP) ≤ 2 x ULN. - BMI ≥ 23 kg/m^2 at screening. Key Exclusion Criteria: - Prior history of ...

3. FT516 in Subjects With Advanced Hematologic Malignancies - Mayo Clinic

   Known allergy to the following FT516 components: albumin (human) or DMSO. Presence of any medical or psycho-social issues that are likely to interfere with ...

4. Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer - Mayo Clinic

   - Albumin >= 2.5 g/dL (=< 15 days prior to registration) - Alanine aminotransferase (ALT) and aspartate transaminase (AST) =< 2.5 x upper limit of normal ...

5. Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer - Mayo Clinic

   Albumin ≥ 3.0 g/dL. Patients known to be Human immunodeficiency virus (HIV)+ are permitted. Patients with CD4>200 and Serum HIV viral load of < 200 copies ...

6. Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations - Mayo Clinic

   Serum albumin ≥ 3.5 g/dL. Subjects with tumors potentially highly sensitive to tipifarnib (HRAS mutant VAF ≥35%) may be enrolled despite a serum albumin ...

7. A Study of the SynCardia Temporary Total Artificial Heart Used as End Point Therapy - Mayo Clinic

   Have cardiac cachexia (e.g., pre-albumin <17, fragility, and catabolic/anabolic imbalance); A comorbidity that has a poor prognosis of survival beyond six ...

8. Study to Evaluate CCS1477 in Haematological Malignancies - Mayo Clinic

   Serum albumin > 2.5 g/dL. Exclusion Criteria: Any investigational agent, chemotherapy, immunotherapy or anticancer agents from a previous clinical study ...

9. Vorinostat, Temozolomide, or Bevacizumab in Combination with Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients with Newly Diagnosed High-Grade Glioma - Mayo Clinic

   Serum albumin ≥ 2 g/dL; PT INR ≤ 1.5 times ULN; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception during all ...

10. A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM - Mayo Clinic

    - Albumin ≥ 3 g/dl. - Potassium ≥ lower limit of normal (LLN). - Serum total calcium (correct for serum albumin) or ionized calcium ≥ LLN. - Estimated ...